Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

When applying the treatment policy estimand 2, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...